Skip to main content
SpringerLink
Log in

Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment

  • Chapter
Antibodies

  • 297 Accesses

Abstract

In recent years, the advent of new tumor-targeting vectors such as monoclonal or bispecific antibodies has resulted in the development of a new generation of therapeutic radiopharmaceuticals and an increasing research interest in this field. However, the emphasis in the overwhelming majority of such studies has been on efficacy in clinical conditions or in animal models of human cancers, and little consideration has been given to the effects of the combination of these antibodies and radiation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abbott, D.W. & Holt, J.T. (1999). Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation. J Biol Chem, 274, 2732–42.

    Article  PubMed  CAS  Google Scholar 

  • Aboud-Pirak, E., Hurwitz, E., Pirak, M.E., Bellot, F., Schlessinger, J. & Sela, M. (1988). Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst, 80, 1605–11.

    Article  PubMed  CAS  Google Scholar 

  • Akimoto, T., Hunter, N.R., Buchmiller, L., Mason, K., Kian Ang, K. & Milas, L. (1999). Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res, 5, 2884–2890.

    PubMed  CAS  Google Scholar 

  • Allred, D.C., Clark, G.M., Molina, R., Tandon, A.K., Schnitt, S.J., Gilchrist, K.W., Osborne, C.K., Tormey, D.C. & McGuire, W.L. (1992). Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol, 23, 974–9.

    Article  PubMed  CAS  Google Scholar 

  • Alroy, I. & Yarden, Y. (1997). The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett, 410, 83–6.

    Article  PubMed  CAS  Google Scholar 

  • Auer, K.L., Park, J.S., Seth, P., Coffey, R.J., Darlington, G., Abo, A., McMahon, M., Depinho, R.A., Fisher, P.B. & Dent, P. (1998). Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-l/WAFl-null mice, but not in hepatocytes from pl6rNK4a-null mice. Biochem J, 336, 551–60.

    PubMed  CAS  Google Scholar 

  • Azria, D., Dorvillius, M., Gourgou, S., Martineau, P., Robert, B., Pugnière, M., Delard, R., Ychou, M., Dubois, J.B. & Pèlegrin, A. (2003a). Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int J Radiat Oncol Biol Phys, 55, 1363–73.

    Article  PubMed  CAS  Google Scholar 

  • Azria, D., Larbouret, C., Martineau, P., Robert, B., Aillères, N., Ychou, M., Dubois, J.B. & Pèlegrin, A. (2003b). A Bispecific antibody against tumor necrosis factor alpha and carcinoembryonic antigen (CEA) to enhance radiation therapy in CEA-expressing digestive tumors.Int J Radiat Oncol Biol Phys, In Press.

    Google Scholar 

  • Azria, D., Labouret, C, Garambois, V., Kramar, A., Martineau, P., Robert B., Aillères, N., Ychou, M., Dubois, J., & Pelegrin, A., (2004). Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a biospecific antibody in human pancreatic cancer: Brit J Cancer, In press

    Google Scholar 

  • Balaban, N., Moni, J., Shannon, M., Dang, L., Murphy, E. & Goldkorn, T. (1996). The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta, 1314, 147–56.

    Google Scholar 

  • Barker, F.G., 2nd, Simmons, M.L., Chang, S.M., Prados, M.D., Larson, D.A., Sneed, P.K., Wara, W.M., Berger, M.S., Chen, P., Israel, M.A. & Aldape, K.D. (2001). EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 51, 410–8.

    Article  PubMed  CAS  Google Scholar 

  • Baselga, J. (2001). The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer, 37 Suppl 4, S16–22.

    Article  PubMed  CAS  Google Scholar 

  • Baselga, J. & Albaneil, J. (2001). Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol, 12, S35–41.

    Google Scholar 

  • Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58, 2825–31.

    PubMed  CAS  Google Scholar 

  • Baselga, J., Pfister, D., Cooper, M.R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H. & Mendelsohn, J. (2000). Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol, 18, 904–14.

    PubMed  CAS  Google Scholar 

  • Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, CA., Moore, J., Rosen, P.P., Twaddell, T., Henderson, I.C. & Norton, L. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 14, 737–44.

    PubMed  CAS  Google Scholar 

  • Berger, M.S., Locher, G.W., Saurer, S., Gullick, W.J., Waterfield, M.D., Groner, B. & Hynes, N.E. (1988). Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res, 48, 1238–43.

    PubMed  CAS  Google Scholar 

  • Beutler, B. & Cerami, A. (1988). The history, properties, and biological effects of cachectin. Biochemistry, 27, 7575–82.

    Article  PubMed  CAS  Google Scholar 

  • Bianco, C., Bianco, R., Tortora, G., Damiano, V., Guerrieri, P., Montemaggi, P., Mendelsohn, J., De Placido, S., Bianco, A.R. & Ciardiello, F. (2000). Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res, 6, 4343–50.

    PubMed  CAS  Google Scholar 

  • Bishop, J.M. (1991). Molecular themes in oncogenesis. Cell, 64, 235–48.

    Article  PubMed  CAS  Google Scholar 

  • Bonner, J.A., Ezekiel, M.P., Robert, F., Meredith, R.F., Spencer, S.A. & Waksal, H.W. (2000a). Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies. In Proc ASCO, Vol. 19 (5F). pp. 4a.

    Google Scholar 

  • Bonner, J.A., Raisch, K.P., Trummell, H.Q., Robert, F., Meredith, R.F., Spencer, S.A., Buchsbaum, D.J., Saleh, M.N., Stackhouse, M.A., LoBuglio, A.F., Peters, G.E., Carroll, W.R. & Waksal, H.W. (2000b). Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol, 18, 47S–53S.

    PubMed  CAS  Google Scholar 

  • Buchsbaum, D.J., Bonner, J.A., Grizzle, W.E., Stackhouse, M.A., Carpenter, M., Hicklin, D.J., Bohlen, P. & Raisch, K.P. (2002). Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys, 54, 1180–93.

    Article  PubMed  CAS  Google Scholar 

  • Carpenter, G. & Cohen, S. (1990). Epidermal growth factor. J Biol Chem, 265, 7709–12.

    PubMed  CAS  Google Scholar 

  • Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N. & Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 72, 3666–70.

    CAS  Google Scholar 

  • Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong, W.L., Rowland, A.M., Kotts, C, Carver, M.E. & Shepard, H.M. (1992). Humanization of an anti-pl85HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA, 89, 4285–9.

    CAS  Google Scholar 

  • Carter, S., Auer, K.L., Reardon, D.B., Birrer, M., Fisher, P.B., Valerie, K., Schmidt-Ullrich, R., Mikkelsen, R. & Dent, P. (1998). Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene, 16, 2787–96.

    Article  PubMed  CAS  Google Scholar 

  • Chen, R.H., Su, Y.H., Chuang, R.L. & Chang, T.Y. (1998). Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene, 17, 1959–68.

    Article  PubMed  CAS  Google Scholar 

  • Chmura, S.J., Mauceri, H.J., Advani, S., Heimann, R., Beckett, M.A., Nodzenski, E., Quintans, J., Kufe, D.W. & Weichselbaum, R.R. (1997). Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res, 57, 4340–7.

    PubMed  CAS  Google Scholar 

  • Ciardiello, F. & Tortora, G. (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7, 2958–70.

    PubMed  CAS  Google Scholar 

  • Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med, 6, 443–6.

    Article  PubMed  CAS  Google Scholar 

  • Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G. & Slamon, D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639–48.

    PubMed  CAS  Google Scholar 

  • David, M., Wong, L., Flavell, R., Thompson, S.A., Wells, A., Lamer, A.C. & Johnson, G.R. (1996). STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J Biol Chem, 271, 9185–8.

    Article  PubMed  CAS  Google Scholar 

  • Dent, P., Reardon, D.B., Morrison, D.K. & Sturgill, T.W. (1995). Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro. Mol Cell Biol, 15, 4125–35.

    PubMed  CAS  Google Scholar 

  • Dent, P., Reardon, D.B., Park, J.S., Bowers, G., Logsdon, C, Valerie, K. & Schmidt-Ullrich, R. (1999). Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell, 10, 2493–506.

    PubMed  CAS  Google Scholar 

  • Di Fiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R. & Aaronson, S.A. (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178–82.

    Article  PubMed  Google Scholar 

  • Dougall, W.C, Qian, X., Peterson, N.C., Miller, M.J., Samanta, A. & Greene, M.I. (1994). The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9, 2109–23.

    PubMed  CAS  Google Scholar 

  • Franke, T.F., Kaplan, D.R. & Cantley, L.C. (1997). PI3K: downstream AKTion blocks apoptosis. Cell, 88, 435–7.

    Article  PubMed  CAS  Google Scholar 

  • Ghosh, S., Strum, J.C, Sciorra, V.A., Daniel, L. & Bell, R.M. (1996). Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J Biol Chem, 271, 8472–80.

    Article  PubMed  CAS  Google Scholar 

  • Goldkorn, T., Balaban, N., Shannon, M. & Matsukuma, K. (1997). EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta, 1358, 289–99.

    Article  PubMed  CAS  Google Scholar 

  • Goldstein, N.I., Prewett, M., Zuklys, K., Rockwell, P. & Mendelsohn, J. (1995). Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res, 1, 1311–8.

    PubMed  CAS  Google Scholar 

  • Grandis, J.R., Drenning, S.D., Zeng, Q., Watkins, S.C., Melhem, M.F., Endo, S., Johnson, D.E., Huang, L., He, Y. & Kim, J.D. (2000). Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA, 97, 4227–32.

    CAS  Google Scholar 

  • Gridley, D.S., Archambeau, J.O., Andres, M.A., Mao, X.W., Wright, K. & Slater, J.M. (1997). Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res, 9, 217–27.

    PubMed  CAS  Google Scholar 

  • Gridley, D.S., Hammond, S.N. & Liwnicz, B.H. (1994). Tumor necrosis factor-alpha augments radiation effects against human colon tumor xenografts. Anticancer Res, 14, 1107–12.

    PubMed  CAS  Google Scholar 

  • Gupta, A.K., McKenna, W.G., Weber, C.N., Feldman, M.D., Goldsmith, J.D., Mick, R., Machtay, M., Rosenthal, D.I., Bakanauskas, V.J., Cerniglia, G.J., Bernhard, E.J., Weber, R.S. & Muschel, R.J. (2002). Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res, 8, 885–92.

    PubMed  Google Scholar 

  • Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A. & Carraway, K.L., 3rd. (1994). Insect cell-expressed pl80erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA, 91, 8132–6.

    CAS  Google Scholar 

  • Haimovitz-Friedman, A. (1998). Radiation-induced signal transduction and stress response. Radiat Res, 150, S102–8.

    Article  PubMed  CAS  Google Scholar 

  • Hallahan, D.E., Beckett, M.A., Kufe, D. & Weichselbaum, R.R. (1990). The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys, 19, 69–74.

    Article  PubMed  CAS  Google Scholar 

  • Hambek, M., Solbach, C, Schnuerch, H.G., Roller, M., Stegmueller, M., Sterner-Kock, A., Kiefer, J. & Knecht, R. (2001). Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res, 61, 1045–9.

    PubMed  CAS  Google Scholar 

  • Helson, L., Helson, C. & Green, S. (1979). Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp Cell Biol, 47, 53–60.

    PubMed  CAS  Google Scholar 

  • Huang, S.M., Bock, J.M. & Harari, P.M. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res, 59, 1935–40.

    PubMed  CAS  Google Scholar 

  • Huang, S.M. & Harari, P.M. (1999). Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs, 17, 259–69.

    Article  PubMed  CAS  Google Scholar 

  • Huang, S.M. & Harari, P.M. (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res, 6, 2166–74.

    PubMed  CAS  Google Scholar 

  • Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M. & Ullrich, A. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol, 9, 1165–72.

    PubMed  CAS  Google Scholar 

  • Hudziak, R.M., Schlessinger, J. & Ullrich, A. (1987). Increased expression of the putative growth factor receptor pl85HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA, 84, 7159–63.

    CAS  Google Scholar 

  • Hynes, N.E. & Stern, D.F. (1994). The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta, 1198, 165–84.

    PubMed  Google Scholar 

  • Ignatoski, K.M., Lapointe, A.J., Radany, E.H. & Ethier, S.P. (1999). erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology, 140, 3615–22.

    Article  PubMed  CAS  Google Scholar 

  • Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R.K. (2002). Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature, 416, 279–80.

    Article  PubMed  CAS  Google Scholar 

  • Janes, P.W., Daly, R.J., deFazio, A. & Sutherland, R.L. (1994). Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene, 9, 3601–8.

    PubMed  CAS  Google Scholar 

  • Jurianz, K., Maslak, S., Garcia-Schuler, H., Fishelson, Z. & Kirschfink, M. (1999). Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology, 42, 209–18.

    Article  PubMed  CAS  Google Scholar 

  • Kavanagh, B.D., Dent, P., Schmidt-Ullrich, R.K., Chen, P. & Mikkelsen, R.B. (1998). Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation. Radiat Res, 149, 579–87.

    Article  PubMed  CAS  Google Scholar 

  • Klapper, L.N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y. & Sela, M. (1997). A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene, 14, 2099–109.

    Article  PubMed  CAS  Google Scholar 

  • Lane, H.A., Motoyama, A.B., Beuvink, I. & Hynes, N.E. (2001). Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol, 12, S21–2.

    Article  PubMed  Google Scholar 

  • Lin, J.T., Wu, M.S., Shun, CT., Lee, W.J., Sheu, J.C. & Wang, T.H. (1995). Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein. Cancer Res, 55, 1428–30.

    PubMed  CAS  Google Scholar 

  • Marais, R., Light, Y., Paterson, H.F. & Marshall, C.J. (1995). Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. Embo J, 14, 3136–45.

    PubMed  CAS  Google Scholar 

  • Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K., Mendelsohn, J. & Fan, Z. (2000). In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res, 6, 701–8.

    PubMed  CAS  Google Scholar 

  • Moghal, N. & Sternberg, P.W. (1999). Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol, 11, 190–6.

    Article  PubMed  CAS  Google Scholar 

  • Moscatello, D.K., Holgado-Madruga, M., Emlet, D.R., Montgomery, R.B. & Wong, A.J. (1998). Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem, 273, 200–6.

    Article  PubMed  CAS  Google Scholar 

  • Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A. & Mueller, B.M. (1993). Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother, 37, 343–9.

    Article  PubMed  CAS  Google Scholar 

  • Nasu, S., Ang, K.K., Fan, Z. & Milas, L. (2001). C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys, 51, 474–7.

    Article  PubMed  CAS  Google Scholar 

  • Nicholson, R.I., Gee, J.M. & Harper, M.E. (2001). EGFR and cancer prognosis. Eur J Cancer, 37 Suppl 4, S9–15.

    Article  PubMed  CAS  Google Scholar 

  • Nishiguchi, I., Willingham, V. & Milas, L. (1990). Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys, 18, 555–8.

    Article  PubMed  CAS  Google Scholar 

  • Old, L.J. (1988). Tumor necrosis factor. Sci Am, 258, 59–60, 69-75.

    Article  PubMed  CAS  Google Scholar 

  • O’Rourke, D.M., Kao, G.D., Singh, N., Park, B.W., Muschel, R.J., Wu, C.J. & Greene, M.I. (1998). Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc. Natl. Acad.Sci. USA, 95, 10842–10847.

    Google Scholar 

  • Park, O.K., Schaefer, T.S. & Nathans, D. (1996). In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA, 93, 13704–8.

    CAS  Google Scholar 

  • Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., Baly, D., Baughman, S.A., Twaddell, T., Glaspy, J.A. & Slamon, D.J. (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-pl85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol, 16, 2659–71.

    PubMed  CAS  Google Scholar 

  • Peng, D., Fan, Z., Lu, Y., DeBlasio, T., Scher, H. & Mendelsohn, J. (1996). Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIPl and induces Gl arrest in prostatic cancer cell line DU 145. Cancer Res, 56, 3666–9.

    PubMed  CAS  Google Scholar 

  • Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B.Y., Hicklin, D.J., Radinsky, R. & Dinney, C.P. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res, 5, 257–65.

    PubMed  CAS  Google Scholar 

  • Perry, J.E., Grossmann, M.E. & Tindall, D.J. (1998). Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate, 35, 117–24.

    Article  PubMed  CAS  Google Scholar 

  • Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B. & Kerbel, R.S. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol, 151, 1523–30.

    PubMed  CAS  Google Scholar 

  • Pietras, R.J., Poen, J.C., Gallardo, D., Wongvipat, P.N., Lee, H.J. & Slamon, D.J. (1999). Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res, 59, 1347–55.

    PubMed  CAS  Google Scholar 

  • Prewett, M., Rothman, M., Waksal, H., Feldman, M., Bander, N.H. & Hicklin, D.J. (1998). Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res, 4, 2957–66.

    PubMed  CAS  Google Scholar 

  • Radinsky, R., Risin, Fan, Dong, Bielenberg, Bucana & Fidler. (1995). Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res, 1, 19–31.

    PubMed  CAS  Google Scholar 

  • Ram, T.G. & Ethier, S.P. (1996). Phosphatidylinositol 3-kinase recruitment by pl85erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ, 7, 551–61.

    PubMed  CAS  Google Scholar 

  • Robert, B., Mach, J.P., Mani, J.C., Ychou, M., Folli, S., Artus, J.C. & Pelegrin, A. (1996). Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res, 56,4758–65.

    PubMed  CAS  Google Scholar 

  • Ruegg, C, Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P. & Lejeune, F.J. (1998). Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med, 4, 408–14.

    Article  PubMed  CAS  Google Scholar 

  • Saleh, M.N., Raisch, K.P., Stackhouse, M.A., Grizzle, W.E., Bonner, J.A., Mayo, M.S., Kim, H.G., Meredith, R.F., Wheeler, R.H. & Buchsbaum, D.J. (1999). Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Ratiopharm, 14, 451–63.

    Article  CAS  Google Scholar 

  • Santana, P., Pena, L.A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E.H., Fuks, Z. & Kolesnick, R. (1996). Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell, 86, 189–99.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt, M., McWatters, A., White, R.A., Groner, B., Wels, W., Fan, Z. & Bast, R.C., Jr. (2001). Synergistic interaction between an anti-pl85HER-2 Pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol, 80, 145–55.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt-Ullrich, R.K., Dent, P., Grant, S., Mikkelsen, R.B. & Valerie, K. (2000). Signal transduction and cellular radiation responses. Radiat Res, 153, 245–57.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt-Ullrich, R.K., Mikkelsen, R.B., Dent, P., Todd, D.G., Valerie, K., Kavanagh, B.D., Contessa, J.N., Rorrer, W.K. & Chen, P.B. (1997). Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene, 15, 1191–7.

    Article  PubMed  CAS  Google Scholar 

  • Schnurch, H.G., Stegmuller, M., Vering, A., Beckmann, M.W. & Bender, H.G. (1994). Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor. Eur J Cancer, 4, 491–6.

    Article  Google Scholar 

  • Sersa, G., Willingham, V. & Milas, L. (1988). Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer, 42, 129–34.

    Article  PubMed  CAS  Google Scholar 

  • Shak, S. (1999). Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol, 26, 71–7.

    PubMed  CAS  Google Scholar 

  • Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J. & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783–92.

    Article  PubMed  CAS  Google Scholar 

  • Slichenmyer, W.J. & Fry, D.W. (2001). Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol, 28, 67–79.

    Article  PubMed  CAS  Google Scholar 

  • Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M. & Fox, J.A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol, 26, 60–70.

    PubMed  CAS  Google Scholar 

  • Stackhouse, M.A., Buchsbaum, D.J., Grizzle, W.E., Bright, S.J., Olsen, C.C., Kancharla, S., Mayo, M.S. & Curiel, D.T. (1998). Radiosensitization mediated by a transfected antierbB-2 single-chain antibody in vitro and in vivo. Int J Radiat Oncol Biol Phys, 42, 817–22.

    Article  PubMed  CAS  Google Scholar 

  • Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Palladino, M.A., Jr. & Shepard, H.M. (1985). Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science, 230, 943–5.

    Article  PubMed  CAS  Google Scholar 

  • Teramoto, T., Onda, M., Tokunaga, A. & Asano, G. (1996). Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer, 77, 1639–45.

    PubMed  CAS  Google Scholar 

  • Tokuda, Y., Ohnishi, Y., Shimamura, K., Iwasawa, M., Yoshimura, M., Ueyama, Y., Tamaoki, N., Tajima, T. & Mitomi, T. (1996). In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer, 73, 1362–5.

    Article  PubMed  CAS  Google Scholar 

  • Tombes, R.M., Auer, K.L., Mikkelsen, R., Valerie, K., Wymann, M.P., Marshall, C.J., McMahon, M. & Dent, P. (1998). The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J, 330 (Pt 3), 1451–60.

    PubMed  CAS  Google Scholar 

  • Tse, C., Brault, D. & Etienne, J. (1997). [Current aspects of the evaluation of ERBB2 activation in breast cancer. Therapeutic perspectives]. Ann Biol Clin (Paris), 55, 545–54.

    CAS  Google Scholar 

  • Ullrich, A. & Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203–12.

    Article  PubMed  CAS  Google Scholar 

  • Uno, M., Otsuki, T., Kurebayashi, J., Sakaguchi, H., Isozaki, Y., Ueki, A., Yata, K., Fujii, T., Hiratsuka, J., Akisada, T., Harada, T. & Imajo, Y. (2001). Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer, 94, 474–9.

    Article  PubMed  CAS  Google Scholar 

  • van der Geer, P., Hunter, T. & Lindberg, R.A. (1994). Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol, 10, 251–337.

    Article  PubMed  Google Scholar 

  • Voldborg, B.R., Damstrup, L., Spang-Thomsen, M. & Poulsen, H.S. (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol, 8, 1197–206.

    Article  PubMed  CAS  Google Scholar 

  • Warenius, H.M., Jones, M.D. & Thompson, C.C. (1996). Exit from G2 phase after 2 Gy gamma irradiation is faster in radiosensitive human cells with high expression of the RAF1 proto-oncogene. Radiat Res, 146,485–93.

    Article  PubMed  CAS  Google Scholar 

  • Wollman, R., Yahalom, J., Maxy, R., Pinto, J. & Fuks, Z. (1994). Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys, 30, 91–8.

    Article  PubMed  CAS  Google Scholar 

  • Wu, X., Fan, Z., Masui, H., Rosen, N. & Mendelsohn, J. (1995). Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest, 95, 1897–905.

    Article  PubMed  CAS  Google Scholar 

  • Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T., Koff, A. & Mendelsohn, J. (1996). Involvement of p27KIPl in Gl arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12, 1397–403.

    PubMed  CAS  Google Scholar 

  • Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J. & Greenberg, M.E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270, 1326–31.

    Article  PubMed  CAS  Google Scholar 

  • Yarden, Y. (2001). The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur J Cancer, 37 Suppl 4, S3–8.

    Article  PubMed  CAS  Google Scholar 

  • Yarden, Y. & Ullrich, A. (1988). Growth factor receptor tyrosine kinases. Annu Rev Biochem, 57, 443–78.

    Article  PubMed  CAS  Google Scholar 

  • Zolfaghari, A. & Djakiew, D. (1996). Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-prl) line by inhibition of epidermal growth factor receptor function. Prostate, 28, 232–8.

    Article  PubMed  CAS  Google Scholar 

  • zum Buschenfelde, C.M., Hermann, C, Schmidt, B., Peschel, C. & Bernhard, H. (2002). Antihuman Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody Trastuzumab Enhances Cytolytic Activity of Class I-restricted HER2-specific T Lymphocytes Against HER2-overexpressing Tumor Cells. Cancer Res, 62, 2244–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunociblage des Tumeurs et Ingénierie des Anticorps, EMI 0227 INSERM-Université Montpellier I-CRLC Montpellier, Centre de Recherche en Cancérologie, CRLC Val d’Aurelle -Paul Lamarque, F-34298, Montpellier Cedex 5, France

    David Azria, Christel Larbouret, Bruno Robert, Jean-Bernard Dubois & André Pèlegrin

  2. Department of Radiation Oncology, CRLC Val d’Aurelle- Paul Lamarque, F-34298, Montpellier Cedex 5, France

    David Azria & Jean-Bernard Dubois

  3. Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Suisse

    Mahmut Ozsahin

Authors
  1. David Azria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christel Larbouret
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mahmut Ozsahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Bernard Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. André Pèlegrin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Littlebourne, Kent, UK

    G. Subramanian

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Azria, D., Larbouret, C., Robert, B., Ozsahin, M., Dubois, JB., Pèlegrin, A. (2004). Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment. In: Subramanian, G. (eds) Antibodies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8877-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-8877-5_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4702-6

  • Online ISBN: 978-1-4419-8877-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation